Leo Mascarenhas/cedars-sinai.org
Jan 29, 2025, 12:53
Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas
Leo Mascarenhas, Division Chief and Director of Pediatric Hematology and Oncology at Cedars-Sinai Guerin Children, shared an article on LinkedIn:
“Hot of the press!
Some insight into the implications of stopping treatment in young sarcoma patients!”
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
Authors: Leo Mascarenhas, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 03:12
Sep 4, 2025, 03:01
Sep 4, 2025, 00:02
Sep 3, 2025, 22:35
Sep 3, 2025, 22:09
Sep 3, 2025, 20:48